GlobalData on MSN1mon
Sobi and Enable Injections partner for Aspaveli distribution
Swedish Orphan Biovitrum (Sobi) and Enable Injections have entered a global agreement to develop and distribute Aspaveli (pegcetacoplan) in combination with enFuse. Sobi will distribute the asset ...
PR Newswire1mon
Sobi® and Enable Injections announce agreement to develop and distribute Aspaveli® in combination with enFuse® in Sobi territories
today announced an international development and distribution agreement across Sobi territories for the enFuse® Injector, for the subcutaneous delivery of Aspaveli® (pegcetacoplan). The enFuse ...
pharmaphorum6d
EU gives narrower label to Apellis, Sobi's PNH drug
The EMA approval of Aspaveli comes just over a year after Sobi licensed co-development and ex-US marketing rights to the drug in a $1.25 billion deal. Along with PNH, the partners are also ...
Impressive Turnaround At KORU Medical
KORU Medical Systems is poised for growth with solid revenue increases and multiple growth drivers. Find out why KRMD stock ...
Swedish Orphan Biovitrum AB: Invitation: Sobi's Aspaveli and the Phase 3 VALIANT data in Nephrology call
VALIANT Phase 3 results after presentation at ASN Investors, analysts, and members of the media are invited to a conference call on Tuesday ...
Seeking Alpha14d
Swedish Orphan Biovitrum AB (publ) (BIOVF) Q3 2024 Earnings Call Transcript
At the same time, we continue building our geographic footprint with the launches of Aspaveli, Doptelet, Vonjo, Zynlonta and Gamifant in new markets. This puts Sobi into a position to create ...
Apellis' Q3 Loss Wider Than Expected, Syfovre Drives Revenues Y/Y
Apellis Pharmaceuticals, Inc. APLS incurred third-quarter 2024 loss of 46 cents per share, wider than the Zacks Consensus Estimate of a loss of 32 cents. The company had incurred a loss of $1.17 per ...
Morningstar4d
David Meek is proposed as new Chair of the Board of Directors of Sobi
The Nomination Committee of Swedish Orphan Biovitrum AB (publ) (Sobi®) proposes that David Meek is elected as new Chair of the Board of Directors of Sobi. Sobi intends to convene an Extraordinary ...
Swedish Orphan Biovitrum AB: Sobi Q3 2024 report: Strong growth and significant pipeline momentum
Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the third quarter 2024 Third Quarter 2024 Total revenue increased ...
Apellis Pharmaceuticals Reports Third Quarter 2024 Financial Results
Generated $196.8 million in 3Q 2024 revenues, including $176.6 million in U.S. net product salesGrew SYFOVRE® (pegcetacoplan injection) demand by ...
Pivotal VALIANT results presented at Kidney Week show pegcetacoplan treatment effect in patients with C3G / primary IC-MPGN
Sobi® (STO: SOBI) and Apellis Pharmaceuticals, Inc. today announced that detailed data from the phase 3 VALIANT study were presented as an ...
Sobi Q3 2024 report: Strong growth and significant pipeline momentum
Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the third quarter 2024 Total revenue increased 33 per cent, 39 per cent at constant exchange rates, (CER) 1, to SEK 6,894 M (5 ...